J.P. Morgan Life Sciences Private Capital names Bruce N. Rogers venture partner
Reuters2026/08/18 13:03- JPMorgan appointed Bruce N. Rogers as venture partner at J.P. Morgan Life Sciences Private Capital.
- Rogers is president and CEO of a precision immunology portfolio company backed by the unit.
- He previously led Morphic Therapeutic, joining in 2016 as chief scientific officer, before its USD 3.2 billion sale to Eli Lilly in 2024.
- Rogers later served at Eli Lilly as senior vice president and CEO of Morphic, overseeing integration of the business.
- Earlier roles included head of neuro-opportunities at Pfizer, with 16 years in medicinal chemistry at Pfizer and Pharmacia.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Extreme level of 8,500 emerges! Two top strategists raise S&P 500 target as strong earnings become key support
Despite facing a surge in US Treasury yields surpassing 5% and a slowdown in the AI sector, Wall Street institutions continue to raise their S&P 500 target prices, with the most bullish forecasts reaching up to 8,500 points.
BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences
LG Electronics Gains a Bull on Likely 3Q Earnings Beat -- Market Talk
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
